USANA Health Sciences (NYSE: USNA) and Foamix Pharmaceuticals (NASDAQ:FOMX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.
Volatility & Risk
USANA Health Sciences has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Foamix Pharmaceuticals has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500.
This table compares USANA Health Sciences and Foamix Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|USANA Health Sciences||5.97%||27.08%||19.75%|
Insider & Institutional Ownership
48.3% of USANA Health Sciences shares are held by institutional investors. Comparatively, 57.5% of Foamix Pharmaceuticals shares are held by institutional investors. 53.2% of USANA Health Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a summary of current ratings and price targets for USANA Health Sciences and Foamix Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|USANA Health Sciences||0||1||1||0||2.50|
USANA Health Sciences currently has a consensus target price of $95.00, suggesting a potential downside of 1.45%. Foamix Pharmaceuticals has a consensus target price of $9.67, suggesting a potential upside of 87.70%. Given Foamix Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Foamix Pharmaceuticals is more favorable than USANA Health Sciences.
Valuation and Earnings
This table compares USANA Health Sciences and Foamix Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|USANA Health Sciences||$1.05 billion||2.21||$62.53 million||$4.06||23.74|
|Foamix Pharmaceuticals||$3.67 million||52.69||-$65.71 million||($1.76)||-2.93|
USANA Health Sciences has higher revenue and earnings than Foamix Pharmaceuticals. Foamix Pharmaceuticals is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.
USANA Health Sciences beats Foamix Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc. develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia. Its product lines include USANA Nutritionals Essentials, Optimizers, Foods, Sense-beautiful science and All Other. Its USANA Nutritionals Essentials product line includes vitamin and mineral supplements that provide a foundation of total body nutrition for every age group beginning with children of approximately one year. Its Optimizers product line consists of targeted supplements designed to meet individual health and nutritional needs. Its Sense-beautiful science product line includes science-based, personal care products that support skin and hair by providing topical nourishment, moisturization and protection.
Foamix Pharmaceuticals Company Profile
Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103 and FDX104. Its lead product candidate, FMX101, is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104.
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.